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Abstract: The peroxisome proliferator-activated receptor (PPAR) family of transcription factors
has been demonstrated to play critical roles in regulating fuel selection, energy expenditure and
inflammation in skeletal muscle and other tissues. Activation of PPARs, through endogenous fatty
acids and fatty acid metabolites or synthetic compounds, has been demonstrated to have lipid-
lowering and anti-diabetic actions. This review will aim to provide a comprehensive overview of the
functions of PPARs in energy homeostasis, with a focus on the impacts of PPAR agonism on muscle
metabolism and function. The dysregulation of energy homeostasis in skeletal muscle is a frequent
underlying characteristic of inflammation-related conditions such as sepsis. However, the potential
benefits of PPAR agonism on skeletal muscle protein and fuel metabolism under these conditions
remains under-investigated and is an area of research opportunity. Thus, the effects of PPARγ
agonism on muscle inflammation and protein and carbohydrate metabolism will be highlighted,
particularly with its potential relevance in sepsis-related metabolic dysfunction. The impact of PPARδ
agonism on muscle mitochondrial function, substrate metabolism and contractile function will also
be described.
Keywords: skeletal muscle; inflammation; PPARs; substrate metabolism
1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are a group of transcription
factors implicated in wide-ranging cellular functions, including lipid metabolism, inflam-
matory responses and cell proliferation and differentiation [1]. Three PPAR subtypes
exist (PPARα, PPARδ and PPARγ). They are activated in vivo by endogenous fatty acids
and their metabolites and synthetic compounds developed for their lipid-lowering and
anti-diabetic actions. Skeletal muscle is a tissue that displays high metabolic flexibility,
comprising different fibre types that vary according to their contractile and metabolic prop-
erties [2]. For example, slow-twitch type I fibres have a relatively high capillary density,
are rich in mitochondria and possess a relatively high capacity for oxidative metabolism
during contraction. In contrast, fast-twitch type IIx fibres have a lower capillary density
and a high capacity for energy delivery from non-mitochondrial routes during contraction.
Disturbances in skeletal muscle energy homeostasis play a key part in the pathogenesis
of several chronic non-communicable disease conditions, including type 2 diabetes (T2D)
and chronic lung disease. The dysregulation of skeletal muscle energy homeostasis is
also a frequent underlying characteristic of acute inflammation-related conditions, such as
sepsis [3] and surgical trauma. The role of PPAR agonism in modulating skeletal muscle
protein and fuel metabolism in these conditions is relatively poorly understood. Still, the
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potential of such an approach will be addressed in this article. Specifically, this review
will aim to provide an overview of the metabolic regulatory roles of PPARs in energy
homeostasis, with a focus on the impacts of PPARδ agonism on skeletal muscle metabolism
and contractile function, primarily highlighting studies that have involved in vivo/ex vivo
animal models or human volunteers. Furthermore, the focus will be directed towards
the potential role of PPARγ agonism in alleviating muscle inflammation and metabolic
disturbances during sepsis.
2. Metabolic Functions of PPARs and Their Actions in Skeletal Muscle
Peroxisome proliferator-activated receptors (PPARs) are a group of proteins that
belong to the nuclear hormone receptor superfamily of ligand-activated transcription
factors. PPAR transcriptional activity is mediated by heterodimers of PPARs with retinoid X
receptor (RXR), which subsequently bind to DNA sequence elements (PPREs) in regulatory
regions of target genes [4]. Three PPAR subtypes have been identified (PPARα, PPARδ
(also known as PPARβ) and PPARγ [5]. Through their interactions with endogenous lipids
and lipid metabolites, PPARs have been reported to regulate many metabolic processes,
including lipid and glucose homeostasis, cell proliferation and inflammation [1]. Several
endogenous compounds, including n-3 and n-6 fatty acids, eicosanoids and phospholipids,
have been identified as natural ligands of PPARs. In addition to this, activation of PPAR
activity by pharmacological agonists has been identified as a promising treatment strategy
for conditions related to insulin resistance and dyslipidaemia, in part through increased
fatty acid oxidation in skeletal muscle, thereby decreasing overall body fat content [6].
Each PPAR subtype has been attributed to different tissue-specific expression levels
and functions. For example, PPARα is highly expressed in tissue types that undergo signif-
icant fatty acid catabolism, such as brown adipose tissue, heart and liver [7]. Activated by
polyunsaturated fatty acids (PUFA) and leukotriene, PPARα has an important function in
fatty acid catabolism and carbohydrate metabolism [8,9]. Synthetic compounds that act as
agonists of PPARα are known as fibrates, whose actions are important in lipid-lowering
activities and cardio-protection [10,11]. PPARγ, on the other hand, is variably expressed in
adipocytes, macrophages, placenta and other tissues and is activated by specific endoge-
nous fatty acid metabolites (such as 15-deoxy-prostaglandin J2) as well as by a class of
insulin sensitisers known as thiazolidinediones (TZDs) [12]. TZDs have been proven to
be important in the treatment of T2D. While early TZDs (e.g., Troglitazone) were related
to severe hepatic side effects, other newer available TZDs (Rosiglitazone, Pioglitazone)
are not toxic to the liver. PPARγ plays a central role in adipogenesis, whereby the insulin-
sensitising effect of TZDs may be due to new adipose cell recruitment, enabling increased
lipid storage capacity and adipokine secretion [13]. PPARγ activation also regulates the
transcription of genes that promote the synthesis of triglycerides [13]. In patients with
T2D, administration of TZDs successfully improved insulin-stimulated glucose disposal
under euglycaemic-hyperinsulinaemic clamp conditions [14,15], where skeletal muscle
plays a central glucose-lowering role. One mechanism by which TZDs exert their insulin
sensitising actions on skeletal muscle is through the modulation of adipose secretory fac-
tors, such as adiponectin. Increased secretion of adiponectin has been suggested to act as
an insulin sensitiser for liver and skeletal muscle, and this occurs through the activation
of PPARγ [16].
The role of PPARδ has remained relatively unclear until recently, where it has been
associated with a wide range of metabolic functions in vivo [17,18]. It has broad expres-
sion across tissues and is activated by various ligands, such as long-chain fatty acids. A
developmental regulatory role has been identified for PPARδ, as well as regulation of lipid
metabolism [17,18]. It is the predominant isotype in skeletal muscle, where it has been
linked to fuel metabolism, energy expenditure, inflammation, and fibre type switching
through physical exercise [17,19]. Both PPARα and PPARδ have been demonstrated to
regulate genes for proteins involved in fatty acid uptake and oxidation, including lipopro-
tein lipase (LPL), fatty acid-binding protein 3 (FABP), stearoyl-Coenzyme A desaturase
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(SCD)-1 and cluster of differentiation 36 (CD36) [20,21]. During fasting, PPARδ expression
is upregulated in rodent skeletal muscles, which is important in regulating the cellular
uptake and oxidation of free fatty acids (FFA) as an energy source for ATP production [22].
Through their importance in metabolic regulation, the role of all three PPAR subtypes
in skeletal muscle metabolism has been established. For example, one link between PPARs
and metabolic regulation in skeletal muscle appears to be through the upregulation of
pyruvate dehydrogenase kinase 4 (PDK4), a key regulator of the pyruvate dehydrogenase
complex (PDC). The PDC activation status is regulated by various competing PDKs and
pyruvate dehydrogenase phosphatase (PDP) proteins [23]. These covalent processes ul-
timately determine the extent of PDC phosphorylation (i.e., activation). There are four
isoforms of PDK (PDK1-4) and two isoforms of PDP (PDP1 and 2) [24,25]. While PDK1
and PDK3 appear to be mainly expressed in the heart, pancreatic islet cells and kidney,
PDK2 and PDK4 are expressed in most tissues, including heart and skeletal muscle [24].
Selective PDK4 upregulation has been demonstrated in response to starvation conditions
and pathologies such as T2D [26,27], which is thought to be due to changes in FFA avail-
ability in skeletal muscle. An increase in fatty acid oxidation via PPARδ agonism [6], and
starvation [28], is believed to be responsible for the PDK4 transcriptional activation, thereby
inactivating PDC (the rate-limiting enzyme in mitochondrial carbohydrate oxidation). It
should be noted, however, that a lack of association between increases in plasma FFA levels
and muscle PDK4 expression has been reported during fasting in humans [29], with no
observable changes in muscle PPARα expression, indicating that other factors could also
be important in PDK4 upregulation. One such factor could be the Forkhead box class O
(FOXO) family of transcription factors, which has been linked to promoter binding of the
PDK4 gene as a result of FFA-mediated nuclear translocation [30].
In addition to increased availability of endogenous fatty acids and their metabolites
being associated with PPAR activation, inflammation has been proven to be a major site of
PPAR regulation, which can occur through both direct and indirect mechanisms [31]. As
mentioned, PPARs have emerged as targets of drugs used to treat various aspects of the
metabolic syndrome, of which inflammation is an underlying key factor. All three PPAR
isotypes have been shown to exert anti-inflammatory effects during conditions of chronic
low-grade inflammation, characterised by increased circulatory cytokines and acute-phase
proteins [32,33]. PPARα was shown to upregulate the expression of IkB, a factor that
suppresses the nuclear translocation and transcriptional activity of the pro-inflammatory
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) [34]. PPARγ has also
been shown to reduce activation of NF-kB, as well as inhibit pro-inflammatory cytokine
production in T lymphocytes and induction of anti-inflammatory regulatory molecules of
the innate immune system [35].
In summary, all three PPAR subtypes have distinct yet overlapping roles in regulating
metabolic function and inflammation (see Table 1), and synthetic compounds aimed at
activating the PPARs have been developed for their lipid-lowering and anti-diabetic ac-
tions. In skeletal muscle, PPAR activation appears important in the upregulation of PDK4,
thereby demonstrating its essential role in regulating carbohydrate oxidation and energy
homeostasis. The following section of this review will focus in more detail on the impact of
PPARδ agonism on muscle metabolism and contractile function and PPARγ agonism on
muscle metabolism and inflammation.
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Table 1. Regulation of lipid and carbohydrate metabolism by PPARs in skeletal muscle, adipose
tissue and liver.
Skeletal Muscle Liver Adipose
PPARδ + FA oxidation−carbohydrate oxidation
+ FA oxidation
− lipogenesis + FA oxidation








PPARα + FA oxidation + FA oxidation− lipid storage
3. PPARδ Agonism and Skeletal Muscle Metabolism, Contractile Function and Inflammation
Several in vivo animal studies have been performed with the aim of determining
the impact of PPARδ agonism on skeletal muscle metabolism and function. We previ-
ously demonstrated in our laboratory that 6 days of administration of the PPARδ agonist,
GW610742 [36], resulted in increased activity of β-hydroxy acyl-CoA dehydrogenase
(β-HAD) in resting rat soleus muscle, which is a key step in β-oxidation in the mito-
chondria. Compared with control animals, these changes were paralleled by increased
expression of muscle PDK2 and PDK4 mRNA and PDK4 protein expression. Thus, ev-
idence points towards PPAR activation in skeletal muscle being, in part, important in
mediating FFA-induced PDK4 upregulation in skeletal muscle, thereby contributing to
PDC inhibition, suppressing PDC-regulated carbohydrate oxidation, and switching fuel se-
lection towards fat oxidation in skeletal muscle (Figure 1). We also measured the impact of
GW610742 on muscle growth-related pathways since FOXO1, which plays a part in PDK4
upregulation, has also been suggested to increase transcription of MAFbx and MuRF1,
thereby activating ubiquitin-proteasome mediated muscle proteolysis [37]. In keeping
with this, administration of the PPARδ agonist resulted in increases in muscle mRNA
and protein expression of MAFbx and MuRF1, suggesting that potentially the induction
of muscle atrophy signalling is another consequence of PPARδ agonism. Collectively,
the findings pointed to PPARδ agonism being involved in the regulation of muscle fuel
selection and the induction of a muscle atrophy programme via a single common signalling
pathway. It should be stated, however, there was no evidence of soleus muscle atrophy
based on the muscle protein:DNA ratio after 6 days of GW610742 administration compared
with control.
In line with the above findings relating to a PPARδ agonism induced switch in muscle
fuel selection away from carbohydrate to increased fat oxidation, in another study, mice
treated with the PPARδ agonist GW501516 exhibited increased PGC-1α levels, and im-
proved prolonged low-intensity wheel-running performance. They also saw hypertrophy
of oxidative slow-twitch myofibres, which are rich in mitochondria, perhaps suggesting
increased reliance on the catabolism of FA through mitochondrial beta-oxidation [38].
However, we further reported that when muscle contraction was increased to an intensity
that necessitates carbohydrate to become an obligate fuel for contraction, PPARδ agonism
negatively affected contractile function in rats [39]. Specifically, male Wistar rats received
the PPARδ agonist GW610742X (or vehicle) for 6 days. The gastrocnemius–soleus–plantaris
muscle group was isolated and subjected to submaximal electrically evoked contraction
using a perfused hindlimb model. The contraction intensity was fixed to guarantee car-
bohydrate become an essential fuel, and PDC activity was increased, ensuring pyruvate
derived acetyl group delivery to the mitochondrion [40]. We observed that PDC activity
during contraction was significantly less with the PPARδ agonist than control, while anaer-
obic metabolism (reflected by phosphocreatine hydrolysis and lactate accumulation) was
greater. We proposed that this collectively accounted for the observed impaired contractile
function with GW610742X agonist, indicating that PPARδ agonism can impair the contrac-
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tile muscle function by inhibiting carbohydrate oxidation during muscle contraction where
carbohydrate is an obligate fuel.
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Figure 1. Activation of PPARδ in skeletal muscle. Increased free fatty acids (FFA) and their metabo-
lites enter skeletal muscle via the FFA transporter CD36, resulting in the formation of a heterodimer
of PPARδ and retinoid X receptor (RXR), and subsequent activation of PPARδ-dependent genes, such
as pyruvate dehydrogenase kinase 4 (PDK4) (and CD36 itself). Activation of PDK4 can result in
reduced rates of glucose oxidation as well as increased fatty acid oxidation in mitochondria.
We have also sought to determine whether PPAR transcription factors may be nec-
essary for the high-fat feeding induced inhibition of PDC activation and carbohydrate
oxidation during submaximal exercise in humans [41,42]. Healthy male volunteers were
given a control diet or an iso-caloric high-fat diet (HFD). They underwent 60 min of sub-
maximal exercise at an intensity equivalent to 75% maximal oxygen uptake. There was a
relative increase in expression of PDK4 in muscle with HFD compared to control, alongside
reduced PDC activation in muscle. Exercise increased PDC activity and carbohydrate
utilisation with both diets, but these measures were diminished with the HFD. In terms of
PPAR expression, there was no effect of the high-fat diet on the mRNA expression of PPARδ.
However, PPARγ and PPARα were increased at rest, though this increase was not apparent
during exercise. Of note, the expression of PPARα mRNA was lower in another group
of volunteers that underwent a HFD but were also treated with dichloroacetate (DCA), a
potent inhibitor of PDK2 and PDK4 and, therefore, a stimulator of PDC activity, which
restored carbohydrate oxidation during exercise in this group. Thus, in humans, these
results appear to suggest there may not be significant involvement of PPARs in increasing
muscle PDK4 expression, although muscle protein levels of each PPAR were not measured.
Following these findings, further work from our laboratory studied the role of PPARδ
(and FOXO1) in palmitate-induced PDC inhibition and carbohydrate use using a skeletal
muscle cell model [43]. Myotubes were treated with palmitate for 16 hrs in the presence
or absence of continuous electrical pulse stimulation, the latter having been shown to
increase glucose uptake a d carbohydrate oxidation in muscle cells [44,45], and there-
fore potentially having the capacity to reverse p lmitate-mediated inhibition of PDC. It
was obs rved th t palmitate reduced glucose uptake, PDC activity and maximal rates
of p lmitate derived mitochondrial ATP production whilst also increasi g PDK4, PPARδ
and PPARα proteins. There was lso a significant reduction in the m g itude of FOXO1
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phosphorylation, indicating its nuclear translocation and subsequent activation. Electrical
pulse stimulation reversed many palmitate-induced changes to carbohydrate oxidation and
was associated with reduced PDK4 protein and reduced PPARδ (but not PPARα) protein
content. Collectively, while more work is required to elucidate the relative importance of
PPARδ and FOXO1 transcription factors in mediating PDK4 transcription, particularly in
humans, these findings indicate their potential roles in palmitate-induced impairments in
PDC activity and carbohydrate oxidation in skeletal muscle.
As discussed earlier, all three PPAR subtypes have the potential for treating inflamma-
tory states, with their anti-inflammatory effects well characterised [31,32]. Based upon this,
targeting PPARs could potentially represent an attractive avenue for alleviating inflamma-
tion and metabolic disturbances during conditions such as sepsis. Fibrates are proven to
be beneficial in treating dyslipidaemia. They may lower circulating triglyceride levels in
the blood by inducing hepatic fatty acid oxidation and increasing levels of high-density
lipoproteins [10,11]. TZDs have also proven antidiabetic effects, though their clinical use
and development has been limited due to adverse side effects (increased risk of congestive
heart failure, weight gain, increased risk of bone fracture). However, inflammation associ-
ated with the pathophysiology of T2D is typically chronic and low-grade, while sepsis is an
acute, high-grade inflammatory condition, which may increase their utility in this scenario.
Sepsis is characterised by an uncontrolled host response to an infection and remains a
major cause of morbidity (including muscle atrophy and insulin resistance) and mortality
worldwide [46]. Ongoing work aims to understand its pathophysiology and develop novel
therapeutics since current available therapeutic strategies remain limited. In patients with
sepsis, severe metabolic dysregulation occurs, which contributes to sepsis pathophysiology
and resultant organ failure. It has been observed that early and rapid skeletal muscle
wasting can occur with critical illness, which can play a major role in causing the increased
length of hospital stay and delayed recovery [3]. In conjunction with this, trials aimed at
attenuating muscle wasting and improving physical function through either nutritional
support or exercise approaches have proved inconsistent.
It is unclear what causes the decline in muscle protein synthesis early in critical illness
and could feasibly be related to impaired mitochondrial function or tissue content [47].
Decreased substrate utilisation, including both carbohydrate and fatty acids, is a conse-
quence of critical illness and could result in impaired metabolic function in muscle [48].
Infusion or injection of the bacterial endotoxin lipopolysaccharide (LPS) can reproduce
many metabolic changes seen in sepsis [49]. The endotoxemia model, therefore, represents
a relevant physiological model of sepsis. In a rat model of LPS-induced septic shock, tissue
protein expression (renal and cardiac) of cytosolic and nuclear PPARα, PPARδ and PPARγ
and nuclear translocation of these proteins were decreased with LPS [50]. In a rodent model
of septic shock, early administration of a selective RXR agonist (bexarotene) was shown to
prevent LPS-induced decrease in mean arterial pressure, as well as LPS-induced decreases
in tissue PPARα/δ/γ-RXRα heterodimer formation [51]. The concurrent decline in circulat-
ing iNOS and LDH levels led the authors to conclude that activation of PPARα/δ/γ-RXRα
heterodimers contributes to the beneficial effect of bexarotene to prevent the hypotension
associated with inflammation and tissue injury during rat endotoxemia.
In terms of muscle-specific effects of PPARδ agonism on metabolism and inflamma-
tion, there have been few studies to date. In a model using cultured muscle cells, one group
tested the hypothesis that PPARδ upregulates FOXO1 activity in muscle, thereby upreg-
ulating MAFbx and MuRF1 expression during sepsis and glucocorticoid treatment [52].
Activation of PPARδ in myotubes resulted in increased atrophy along with protein degrada-
tion and increased FOXO1 activity. Similar changes induced by dexamethasone (used as an
agent to cause atrophy) were prevented by treatment with a PPARδ inhibitor. Furthermore,
a PPARδ inhibitor given to dexamethasone-treated or septic rats prevented muscle wasting.
These findings appear to support the suggestion that PPARδ may regulate activation of a
FOXO1 linked atrophy programme in sepsis-induced muscle wasting.
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Cardiac failure and decreased uptake and oxidation of fatty acids in the heart are
common features of severe sepsis [53]. In a mouse model of sepsis [54], LPS adminis-
tration rapidly caused downregulation of PPARα, PPARδ, as well as isoforms of thyroid
hormone receptor (TR) and RXR (which are required for PPAR transcriptional activity)
in the heart. There were also concurrent decreases in the expression of key fatty acid
transporter/oxidation genes with LPS treatment. Thus, it is possible that these rapid
decreases in the expression of key genes, including PPARα and PPARδ, are important in
driving the reductions in cardiac fatty oxidation and myocardial dysfunction in sepsis. The
potential protective effects of PPARδ agonism have been studied in relation to changes
in LPS-induced apoptosis. In cultured rat cardio-myoblast cells, pre-treatment with the
PPARδ agonist GW501516 inhibited increased rates of apoptosis induced by LPS, decreased
activity of caspase-3 and increased nuclear translocation of NF-kB [55]. Furthermore,
GW501516 increased protein expression of haem oxygenase-1 (HO-1), while inhibition of
HO-1 reversed the effects of GW501516 on LPS-induced NF-kB activation. Thus, PPARδ
also has anti-apoptotic effects during an LPS challenge in cardiac cells, potentially through
suppressing NF-kB activation and via HO-1. Whether these observed effects of PPARδ are
relevant to skeletal muscle in terms of inflammation and substrate oxidation during sepsis
and related conditions remains to be determined.
To summarise, the effects of PPARδ agonism on skeletal muscle appear to be pre-
dominantly related to the switching of fuel utilisation towards increased oxidation of fatty
acids, as well as declined carbohydrate oxidation. This can result in impaired function
during prolonged muscle contraction where carbohydrate is an obligate fuel. Activation of
PPARδ may also induce atrophy-related programmes in skeletal muscle. During sepsis,
however, declines in PPAR activity may underlie some of the declines in FFA oxidation
in various tissues, indicating that there may be some benefit to PPARδ agonism during
these conditions.
4. PPARγ Agonism and Skeletal Muscle Metabolism and Inflammation
As described earlier, PPARγ plays a central role in adipogenesis, and TZDs have been
shown to increase insulin-stimulated glucose disposal in T2D patients effectively. The
effects of PPARγ agonism on skeletal muscle metabolic regulation remains poorly under-
stood. One study assessed the impact of the PPARγ agonist, Rosiglitazone, on fatty acid
transport and oxidation in rat muscle [56]. Seven days of rosiglitazone infusion (1 mg/day)
did not alter the rate of fatty acid transport into muscle, but did increase rates of fatty acid
oxidation in subsarcolemmal and intermyofibrillar mitochondria. This was accompanied
by increases in mitochondrial FAT/CD36 protein, with no changes in citrate synthase or
β-HAD activity. The effects of PPARγ activation on lipid metabolism were also studied in
human skeletal muscle in vivo [57]. Long-chain fatty acid composition and stearoyl-CoA
desaturase 1 (SCD1) were examined following 8 weeks of Rosiglitazone treatment in men
with impaired glucose tolerance, with muscle biopsies and hyperinsulinaemic-euglycaemic
clamps being carried out before and after rosiglitazone administration. Alongside an
increase in insulin sensitivity, SCD1 expression was increased in muscle samples with
rosiglitazone treatment. In addition, there was a shift in lipid composition from saturated
long-chain fatty acids to unsaturated fatty acids in muscle. These findings clearly indicate
a role for PPARγ activation in modulating lipid metabolism in skeletal muscle in vivo.
The impact of TZDs on skeletal muscle lipid and carbohydrate metabolism has been
predominantly studied in relation to animal models of T2D [58–60], and patients with
T2D [61–63]. In one model of obese Zucker rats [59], 6 weeks of rosiglitazone administra-
tion improved glucose tolerance in obese rats, while intramuscular triglyceride content,
which was higher in obese compared with lean animals, was further increased following
rosiglitazone treatment. There were also increases in skeletal muscle diacylglycerol and
ceramide with rosiglitazone treatment, indicating that under these conditions, Rosiglita-
zone increased insulin sensitivity in obese rats, but this was not through reduced fatty acid
accumulation in muscle.
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In a study with T2D patients, the effects of three months of rosiglitazone treatment
on insulin sensitivity and lipid metabolism were examined during a hyperinsulinaemic-
euglycaemic clamp [61]. Insulin-stimulated glucose disposal was improved following
rosiglitazone treatment, and reduced plasma fatty acid concentrations and increased ex-
tramyocellular lipid levels were observed. Rosiglitazone also promoted increased in-
sulin sensitivity in peripheral adipocytes, indicating that enhanced insulin sensitivity
through PPARγ agonism in humans may occur predominantly via improving adipocyte
insulin sensitivity, leading to lipid redistribution from insulin-sensitive organs to peripheral
adipocytes. In another study with T2D patients, further insight into the mechanisms by
which TZDs improved insulin sensitivity in T2D was examined. Pioglitazone treatment for
6 months improved insulin-stimulated glucose disposal in T2D patients. In muscle tissue,
there were increases in AMPK and acetyl-CoA carboxylase (ACC) phosphorylation with pi-
oglitazone and increased expression of genes important in fat oxidation and mitochondrial
function. These findings suggest some of the mechanisms by which TZDs improve skeletal
muscle insulin sensitivity may involve stimulation of AMPK signalling and fat oxidation.
As described in a previous section, more work is required to determine whether
different types of PPAR drug targets may have any potential benefit in alleviating inflam-
mation in sepsis, thereby potentially preventing and/or improving certain deleterious
consequences associated with the condition. In relation to specifically PPARγ agonists
impacting on targeting inflammation, we previously assessed the impact of Rosiglitazone
on muscle carbohydrate and protein metabolism in a rat model of LPS-induced endotox-
aemia [64]. Initial work from our laboratory [65–67] demonstrated that dysregulation of
the Akt/FOXO signalling pathway was important in mediating the development of muscle
atrophy during LPS-induced endotoxaemia, specifically through activation of ubiquitin
ligases MAFbx and MuRF1. We also proposed that the Akt/FOXO signalling pathway
represents a site of molecular crosstalk between insulin and atrophy-related signalling pro-
cesses during endotoxaemia through FOXO-mediated upregulation of PDK4 and reduced
activity of PDC.
To assess the effects of PPARγ agonism on muscle protein and carbohydrate
metabolism during endotoxaemia, rats were fed standard chow containing Rosiglitazone
(8.5 ± 0.1 mg·kg−1·day−1) for 2 weeks before and during 24 h continuous intravenous infu-
sion of LPS (15 µg·kg−1·h−1) or saline [64]. In terms of muscle inflammation, Rosiglitazone
blunted LPS-induced increases in TNF-α and IL-6 mRNA expression. We also examined the
subsequent impact of Rosiglitazone on LPS-induced changes in muscle protein degradation
pathways, specifically, ubiquitin-proteasome-mediated protein breakdown. Increased ex-
pression of key proteolytic regulators (MAFbx and MurF1 mRNA), and activity of the 20S
proteasome, were suppressed in the rosiglitazone-treated group of animals in the presence
of endotoxaemia. In carbohydrate oxidation, LPS-induced increases in PDK4 gene expres-
sion and muscle lactate content were also suppressed with rosiglitazone administration.
Collectively, these findings indicated that there were metabolic benefits of rosiglitazone
pre-treatment in this LPS model of endotoxaemia, reflected by blunted muscle cytokine
accumulation, muscle protein loss and lactate accumulation (Figure 2).
While few studies have assessed the impact of PPARγ agonists on skeletal muscle in-
flammation and metabolism during inflammatory disorders such as sepsis, there has been
some work surrounding the protective effects of PPARγ on myocardial dysfunction in sep-
sis. One study in mice (using LPS administration as a sepsis model) investigated whether
reduced fatty acid oxidation is the underlying cause for cardiac dysfunction in sepsis [68].
LPS administered to mice rapidly decreased cardiac fatty acid oxidation in conjunction
with inducing cardiac dysfunction, while gene expression of PPARγ was downregulated.
Moreover, activation of PPARγ using a transgenic mouse model (cardiomyocyte-specific
PPARγ expression induced by the alpha-myosin heavy chain promoter) protected against
cardiac dysfunction induced by LPS, while fatty acid oxidation was not reduced with LPS
exposure in these animals. Interestingly, the expression of inflammation-related genes
(IL-1α, IL-1β, IL-6 and TNF-α) in response to LPS treatment was similar to wild-type mice.
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Rosiglitazone administration in wild-type mice similarly increased fatty acid oxidation,
improved cardiac function after treatment with LPS and improved survival, despite not
suppressing the expression of cardiac markers of inflammation. These findings are, there-
fore, promising in terms of the use of PPARγ agonists in sepsis treatment. Still, more work
should be done on their mechanism of action and delineating whether their beneficial
effects occur through their anti-inflammatory actions.
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Figure 2. I pact of PPARγ agonism in skeletal muscle during LPS-induced endotoxaemia. Treatment
with PPARγ agonists during endotoxaemia suppresses production of pro-inflammatory cytokines
(e.g., tumour necrosis factor α: TNF-α). This results in reduced suppression of muscle AKT, and
reduced transcriptional activity of Forkhead Box O (FOXO) transcription factors. Reduced activity of
FOXO leads to suppression of factors important in increased muscle atrophy (MAFbx and MuRF1)
as well as PDK4, a key protein in PDC inhibition.
In relation to myocardial dysfunction, a separate study in rats assessed the mechanism
of PPARγ-mediated cardiac protective effects in sepsis [69]. Using rats subjected to caecal
ligation and puncture (CLP), a PPARγ agonist (Rosiglitazone) and antagonist (T0070907)
were used. The model of sepsis used resulted in significant impairments in cardiac function,
with evidence of tissue apoptosis, necrosis and upregulated proinflammatory cytokines.
Activation of PPARγ prevented these changes while blocking its activity exacerbated
the differences and further reduced survival rates. These results provide other evidence
that Rosiglitazone can exert beneficial effects related to reduced cardiac inflammation
and cell death. A separate recent study further examined the effects of Rosiglitazone on
sepsis-induced myocardial dysfunction in relation to the NF-κB pathway [70]. Here, a
model of sepsis was established using female Sprague-Dawley rats, after which one group
was administered 3 mg/mg rosiglitazone (daily, for 3 days). Rosiglitazone successfully
decreased the number of apoptotic cells in septic animals, while in myocardial tissues,
Rosiglitazone lowered TNF-α expression and activity of NF-κB.
To summarise, agonism of PPARγ in vivo appears to improve insulin sensitivity and
may also increase fatty acid oxidation in skeletal muscle. However, improved insulin
sensitivity may not be related to reductions in fatty acid accumulation in muscle tissue
under certain conditions. In relation to inflammatory conditions such as sepsis, PPARγ
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agonists effectively suppress pro-inflammatory cytokine production and appear to be
beneficial in alleviating organ injury and dysfunction, which has promising potential for
therapeutic development.
5. Conclusions and Future Perspectives
To conclude, the PPAR family of transcription factors have wide-ranging critical
regulatory roles in skeletal muscle and other tissues, from inflammation to fuel selection
and contractile function. In terms of PPARδ, evidence suggests that the agonism of PPARδ
appears to be primarily related to the switching of substrate utilisation towards increasing
the use of fatty acids. In contrast, PPARδ agonism can impair muscle contractile function
by inhibiting carbohydrate oxidation during muscle contraction, where carbohydrate is
an obligate fuel. Conversely, there may be benefits to PPARδ agonism during certain
inflammatory conditions, such as sepsis, since declines in PPAR activity may underlie some
of the reductions in FFA oxidation. Similarly, agonism of PPARγ in vivo appears to be an
effective anti-inflammatory strategy during sepsis and has proven beneficial in improving
organ/tissue function in pre-clinical models. Blunting muscle cytokine accumulation
during endotoxaemia in rodents has also been demonstrated to result in metabolic benefits
via reduced muscle wasting and lactate accumulation.
Moving forwards, more studies will be required to better define the mechanistic
roles of all the PPARs in different physiological and pathophysiological conditions. The
potential benefits of PPAR agonism on skeletal muscle protein and carbohydrate/lipid
metabolism during sepsis and other inflammatory conditions remains under-investigated
and is, therefore, a promising area of research opportunity. Studies using dual or pan-PPAR
agonists could also widen the therapeutic potential of these compounds, while cross-tissue
studies will be important in evaluating potential off-target effects. Nevertheless, with
ongoing drug developments and a greater understanding of the wide-ranging functions of
PPARs, these transcription factors will undoubtedly remain critical therapeutic targets for
a multitude of metabolic and inflammatory conditions.
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